Biodesix named Company of the Year by CBSA
Monday November 11, 2019
BOULDER -- Biodesix, Inc. has been named Company of the Year by the Colorado BioScience Association (CBSA).
The company received the honor at the 16th Annual CBSA Awards Dinner on Nov. 7.
CBSA serves as the hub for Colorado’s life science industry with member organizations spanning biotechnology, pharmaceutical, medical device, diagnostic, ag bio, mobile digital health, research, academic, and service providers.
Biodesix was selected as Company of the Year in recognition of the significant milestones the company reached in advancing patient access to novel diagnostic testing in the clinic, and in ongoing development of new tests that address areas of high unmet clinical needs across the continuum of care in lung cancer.
Lung cancer is still the leading cause of cancer death among men and women. In 2018, approximately 234,000 patients were diagnosed and 154,000 died due to lung cancer, which represents more than 25 percent of all cancer deaths in the U.S.
“CBSA’s Annual Awards Dinner highlighted how health innovations from Colorado make a global impact,” said Jennifer Jones Paton, CBSA president and CEO.
“We are proud to honor Biodesix for its innovation and bringing top minds together to strengthen the future of healthcare. As the first company to provide four best-in-class diagnostic tests for patients in lung cancer, Biodesix has demonstrated its commitment to helping physicians and their patients navigate lung cancer therapy decisions.
“CBSA is proud to honor Biodesix for its breakthroughs for patients, leadership in Colorado’s life sciences community and track record of success.”
Key milestones for Biodesix in 2019 include:
- Acquisition of Oncimmune in the U.S. to expand minimally invasive diagnostics to patients in North America with the EarlyCDT Lung test for lung nodule management, adding a 4th blood-based test to the portfolio
- Expanded reach of Nodify XL2 testing for lung nodule management
- Partnership with Thermo Fisher Scientific to develop a next-generation sequencing blood assay
- Patenting of the Biodesix Collection Device (BCD) to improve on ease of blood collection, reduce cost and environmental impact
“Our greatest reward is the positive impact we can have on the lives of patients and their loved ones as they navigate lung cancer treatment decisions,” said Scott Hutton, COO and incoming CEO for Biodesix.
“There is no higher honor than knowing that we played a part in improving the quality of life for a person facing the dreadful disease of lung cancer,” said David Brunel, CEO for Biodesix.
“We are proud to be building a Colorado-based bioscience company with 150 employees. We began as a Colorado startup and this year we celebrated several important milestones. We greatly appreciate the recognition of the Colorado BioScience Association.”